Role of Suppressor of Cytokine Signaling 3 (SOCS 3) in Inflammation-Associated and Sporadic Colorectal Cancer

 

Trainee:

Kate Hamilton

Hamilton

Research Mentor:

Dr. Kay Lund, PhD

Lund

Clinical Co-Mentor:

Dr. Robert Sandler, MD, MPH

sandler
Project Description: Kate Hamilton will determine the relevance of suppressor of cytokine signaling 3 (SOC3) as a possible tumor suppressor in colon cancer. Her laboratory studies use genetically altered mice to define the role of SOC3 in inflammation–associated proliferation. She will translate these basic observations to clinical relevance by asking if low levels of SOC3 expression or epigenetic silencing of SOC3 correlates with increased risk of precancerous lesions in the colons of patients being screened by routine colonoscopy, or in patients with IBD-associated or sporadic dysplasia and neoplasia. Her thesis mentor, Dr. Lund, is a world leader in research on intestinal adaptation. Her clinical co-mentor, Dr. Robert Sandler is a world leader in the epidemiology of colon cancer risk factors and a member of the NIH Digestive Diseases Commission.